Spero Therapeutics Receives $30,000,000 New Funding

  • Feed Type
  • Date
    2/2/2016
  • Company Name
    Spero Therapeutics
  • Mailing Address
    400 Technology Square 10th Floor Cambridge, MA 20139 USA
  • Company Description
    Spero Therapeutics’ vision is to find, develop, and advance groundbreaking therapeutics to meet critical patient needs in infectious disease using a unique business and drug discovery model. Spero Therapeutics is developing first in class therapeutics for treatment of Gram-negative infections.
  • Website
    http://www.sperotherapeutics.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $30,000,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    All six of the previous investors in Spero Therapeutics joined in the Series B round announced today, which will help the startup work toward human trials of what it calls its Potentiator Platform, intended to make existing anti-infective medications more effective in fighting bacteria.
  • M&A Terms
  • Venture Investor
    Accomplice
  • Venture Investor
    SR One
  • Venture Investor
    Merck Capital Ventures
  • Venture Investor
    Lundbeckfond Ventures
  • Venture Investor
    The Kraft Group
  • Venture Investor
    Partners Innovation Fund